PNAClamp™ Mutation Detection Kit EGFR (ver.2)

Lung cancer is categorized into two types; non-small cell lung cancer (NSCLC) with the 80~85% frequency and small cell lung cancer with the 15~20% frequency. Epidermal growth factor receptor (EGFR) is expressed on the surface of epidermal cells and has the tyrosine kinase activity. Overexpression of EGFR is found only in NSCLC and may lead to signal transduction system in cells by causing cell proliferation, tumor-induced neoangiogenesis (formation of new blood vessels) and transition induction. The EGFR tyrosine kinase inhibitor (TKI), gefinitib (Iressa, AstraZenca) or erlotinib (Tarceba, Roche), is effective to inhibit the growth of cancer cells and leads to death of cancer cells and suppression of new blood vessels in lung cancer tissue. Especially, some specific mutations in the ATP-binding domain of EGFR gene have strong positive correlation with the response rate of EGFR-TKIs. Furthermore, NSCLC patients with the EGFR mutations are reported to be more effective to EGFR-TKI and show prolonged survival rate of patients with lung cancer. Therefore, detection of the EGFR mutation is becoming an important prognostic biomarker for drug response, and efficient detection of the EGFR mutation is expected to be highly helpful for increase of survival rate of patients with lung cancer in targeted therapy.

CAT NO.

PNAC-3002

DETAILS

PROCEDURE

• sample preparation
• Extraction of Total DNA
• Amplification of target DNA by Real-Time PCR
• Analysis of Result

COMPATIBLE SAMPE TYPE

COMPATIBLE Real-Time PCR machine

• 

  CFX96
  (Bio-Rad)
  

• 

  LightCycler 480II
  (Roche)
  

• 

  ABI7500
  (Thermo Fisher Scientific)
  

• 

  ABI7900HT
  (Thermo Fisher Scientific)
  

• 

  Rotor-Gene Q
  (Qiagen)
  

REFERENCE

• Kim et al.(2012)Lung Cancer. 75(3):321-325
  
  Detection and comparison of peptide nucleic acid-mediated real-time polymerase chain reaction clamping and direct gene sequencing for epidermal growth factor receptor mutations in patients with non-small cell lung cancer.

  PubMed Article
• Han et al.(2012)J Thorac Oncol. 7(2):355-364
  
  Detection of EGFR Mutation Status in Lung Adenocarcinoma Specimens with Different Proportions of Tumor Cells Using Two Methods of Differential Sensitivity.

  PubMed Article
• Choi et al.(2010)Bull.Korean Chem. Soc. 31(12):3525-3529
  
  PNA-mediated real-time PCR clamping for detection of EGFR mutations

  Article
• Lee et al.(2010)Tuberc Respir Dis. 69:271-278
  
  PNA-Mediated PCR Clamping for the Detection of EGFR Mutations in Non-Small Cell Lung Cancer.

  Article
• Noro et al.(2006)BMC Cancer. 6:277
  
  Gefitinib (IRESSA) sensitive lung cancer cell lines show phosphorylation of Akt without ligand stimulation.

  PubMed Article

INQUIRY